DEMANT’S RE-RATING – LOUD AND CLEAR (ADD; 17% UPSIDE)
29/09/23 -" After a terrible 2022, the situation for MedTechs seemed to be getting better. However, worries again took over, with the sector down c.6% (in ytd terms) vs. c.9% gains for the AV universe. While ..."
Pages
62
Language
English
Published on
29/09/23
You may also be interested by these reports :
09/05/25
Sonova’s full-year results slightly exceeded market expectations, with robust growth across both segments. The promising FY2025-26 outlook was well ...
08/05/25
Qiagen commenced 2025 positively, with robust performance in Diagnostic Solutions and PCR/Nucleic Acid Amplification, although this was partially ...
08/05/25
Demant’s Q1 results met market expectations. Growth in Hearing Care was counterbalanced by weakness in Hearing Aids. Meanwhile, Diagnostics remained ...
07/05/25
DiaSorin’s Q1 results marginally surpassed market expectations, demonstrating good performance across all segments. Profitability improved and ...